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Introduction: Atrial fibrillation (AF) is the most common complication
after cardiac surgery and is responsible for significant morbidity and mortality.
To assess whether preconditioning with renin-angiotensin-aldosterone system
agents could limit myocardial tissue injury, we tested the force of contraction
of human right atrial trabeculae during hypoxia-reoxygenation when exposed
to aldosterone and/or potassium canrenoate.
Materials and methods: We studied the effect of aldosterone and/or
mineralocorticoid receptor (MR) antagonist potassium canrenoate adminis-
tration prior to hypoxia-reoxygenation and in normoxic condition on force
of contraction in 51 human right atrial trabeculae obtained from patients
scheduled for coronary artery bypass surgery or aortic valve replacement.
We also tested if adosterone exposure results in changes in levels of ERK1/2
phosphorylation.
Results: The force of contraction of trabeculae was significantly
reduced by aldosterone administration under normoxic or hypoxia-reoxy-
genation conditions. The rapid onset of this effect – 25 minutes – suggests
a nongenomic mechanism. When compared with controls, potassium can-
renoate by itself was not able to induce cardioprotection. However, coad-
ministration of aldosterone and potassium canrenoate preconditioned
isolated human atrial myocardium exposed to hypoxia – reoxygenation.
This effect could be MR-dependent or not because both aldosterone and
potassium canrenoate have some nongenomic MR-independent actions.
Preliminary results showed that aldosterone exposure increased ERK1/2
phosphorylation levels.
Conclusion: Potassium canrenoate-induced cardioprotection prevents the
deleterious effect of aldosterone on human atrial myocardial tissue. Further
research required to determine the mechanism involved and the potential ben-
eficial in clinical practice in order to reduce the incidence of postoperative
atrial fibrillation.
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Background: Bleeding is associated with higher risk of adverse outcomes
in pulmonary embolism (PE). The “Bleeding Academic Research Consor-
tium” (BARC) developed a classification of events combining laboratory &
clinical parameters, but based on acute coronary syndrome patients. We inves-
tigated whether this classification is applicable in the context of PE, where no
standard bleeding definition exists.
Methods: Prospective, single-center registry of patients with confirmed
PE. We excluded BARC types 1 or 4 bleeding, considered not to be applicable
to the context of PE. BARC type 2 bleeds were defined as any overt bleeding
requiring non-surgical or medical care, or leading to hospitalisation. Type 3
bleeds were defined as drop of >3 g/dL in haemoglobin, any transfusion, tam-
ponnade, intra-cranial hemorrhage, or bleeding requiring surgical intervention.
Type 5 bleeds were defined as any fatal bleed.
Results: From 2007 to 2011, 666 patients with confirmed PE were
included; average age 66±18 years; 52% women; 25% low-risk, 61% interme-
diate-risk and 14% high-risk PE. Treatment was: unfractionated heparin in 93
(14%), enoxaparin in 200 (30%), fondaparinux in 373 (56%). Thrombolysis
was given in 167 (25%). Sixty patients (9%) experienced bleeding (n=13, 43,
4 for BARC types 2, 3, 5 respectively). Main in-hospital events are shown in
table 1. By multivariate analysis, independent predictors of in-hospital death
were: cardiogenic shock (OR 12.6 [4.8-20.8]); chronic obstructive pulmonary
disease (OR 5.27 [2.25-8.43]); acute right ventricular dysfunction (OR 2.98
[1.25-6.96]) and any bleeding (BARC 2,3,5) (OR 3.15 [1.34-7.37]).
Conclusion: Our data suggest that the BARC classification can be applied
to acute PE and that bleeding is associated with unfavourable in-hospital out-
come. We suggest use of the BARC as the standard for classification of
bleeding events in PE.
Table – Results
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BARC type 
2 (A) 
BARC type 
3/5 (B) 
o bleed 
(n=606) (C) 
p (A) vs (C) p (B) vs (C)
Death 2 (15.4%)  7 (15%)  19 (3.1%) 0.034 0.0014
Recurrent PE 0  4 (8.5%)  5 (0.9%)  0.67  <0.0001
Treatment 
escalation
 1 (7.7%) 2 (4.2%) 4 (0.7%) 0.017  0.028
